Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
01:02pm, Monday, 01'st Jun 2026
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses
15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
07:00am, Wednesday, 27'th May 2026
FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exclusivity is effective through August 14,
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
08:05am, Tuesday, 26'th May 2026
GERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
04:52pm, Thursday, 21'st May 2026
Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight c
Precigen: Full Commercial Validation And Room To Run
09:58am, Thursday, 14'th May 2026
Precigen is recommended as a buy due to PAPZIMEOS's early FDA approval, its commercial validation, and astonishingly quick insurer and physician adoption. PGEN's AdenoVerse platform underpins near-ter
Precigen Q1 Earnings Call Highlights
12:14am, Thursday, 14'th May 2026
Precigen NASDAQ: PGEN reported a sharp increase in first-quarter 2026 revenue as the company's first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
10:40pm, Wednesday, 13'th May 2026
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 13'th May 2026
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.07 per share a year ago.
Precigen Reports First Quarter 2026 Financial Results and Business Updates
04:05pm, Wednesday, 13'th May 2026
PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
04:05pm, Thursday, 07'th May 2026
GERMANTOWN, Md., May 7, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
07:00am, Tuesday, 07'th Apr 2026
Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
01:32am, Wednesday, 01'st Apr 2026
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
08:30am, Monday, 30'th Mar 2026
GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve
